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Abstract: Biosynthetic and chemical datasets are the two major pillars for microbial drug discovery in
the omics era. Despite the advancement of analysis tools and platforms for multi-strain metabolomics
and genomics, linking these information sources remains a considerable bottleneck in strain priori-
tisation and natural product discovery. In this study, molecular networking of the 100 metabolite
extracts derived from applying the OSMAC approach to 25 Polar bacterial strains, showed growth
media specificity and potential chemical novelty was suggested. Moreover, the metabolite extracts
were screened for antibacterial activity and promising selective bioactivity against drug-persistent
pathogens such as Klebsiella pneumoniae and Acinetobacter baumannii was observed. Genome sequenc-
ing data were combined with metabolomics experiments in the recently developed computational
approach, NPLinker, which was used to link BGC and molecular features to prioritise strains for
further investigation based on biosynthetic and chemical information. Herein, we putatively identi-
fied the known metabolites ectoine and chrloramphenicol which, through NPLinker, were linked to
their associated BGCs. The metabologenomics approach followed in this study can potentially be
applied to any large microbial datasets for accelerating the discovery of new (bioactive) specialised
metabolites.
Keywords: Actinobacteria; marine; Polar; genomics; metabolomics; specialised metabolites
1. Introduction
More than 80 years after the first reported case of sulphonamide-resistant bacterial
strains [1], antibiotic resistance is now a global threat to human health, projected to cause
10 million deaths annually by 2050 [2,3]. Historically, microorganisms have been a source
of over 22,000 biologically active metabolites, including antibiotics, isolated from terrestrial
and marine strains [4]. In particular, the order Actinomycetales (actinomycetes) has been
shown to produce structurally diverse specialised metabolites which exhibit a wide range
of biological activities. Indeed, more than 7000 metabolites have been isolated from the
genus Streptomyces and approximately 3000 metabolites from the “rare” (due to their lower
isolation frequency) actinomycete genera [5]. Actinomycetes have an average genome size
of over 5 Mb. However, this number varies greatly between genomes which can reach
up to 12 Mb in some Streptomyces species [6]. Actinomycetes dedicate 0.8–3.0 Mb of their
whole genome to specialised metabolite production, which has been shown to result in
20–50 Biosynthetic Gene Clusters (BGCs) per strain [7]. A recent study of 21 rare marine
actinomycetes isolated from temperate and sub-tropic marine environments unveiled
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diverse and numerous BGCs, with Actinomadura spp. and Nocardia spp. containing 44
and 38 BGCs per strain, respectively. Interestingly, only three percent of the BGC families
overlapped between the Streptomyces strains and the rare actinomycetes, suggesting an
exciting resource for biosynthetic novelty [8]. Moreover, analysis of 119 genomes of the
rare actinomycete genus Salinispora derived from various sub-tropic and tropic locations
revealed 176 BGCs, of which only 24 were linked to their respective products [9], indicating
a potential resource for novel metabolites.
Although actinomycetes from the (sub-)tropics have been extensively studied and
shown to be a promising source of biological and chemical novelty, Actinobacteria isolated
from Polar regions also show potential for affording new biologically active specialised
metabolites. Actinobacteria accounted for 5% of the total microbial community present in
Antarctic sediment samples as revealed by high-throughput 16S rRNA gene sequencing,
with the Salinibacterium genus being amongst the most abundant [10]. In terms of isolating
rare actinomycetes from Polar habitats, a study of ancient Antarctic and sub-Arctic sediment
samples yielded 50 bacterial strains, of which 39 belonged to rare actinomycetes genera
(Microbacterium, Dietzia, Rhodococcus, and Pseudonocardia) [11]. Regarding the chemical
potential, molecular networking indicated rare actinomycetes from sub-Arctic and Antarctic
sediments to be a rich source of metabolites [11,12]. Since 2001, a total of twenty-nine
new metabolites have been isolated from Antarctic and sub-Arctic bacteria, with 13 being
produced by marine actinomycetes [13]. For example, the rare actinomycete Nocardia
dassonvillei BM-17 isolated from an Arctic sediment sample yielded a new phenazine
derivative with significant antifungal and cytotoxic activity [14]. Two new α-pyrones
were isolated from an Antarctic Nocardiopsis strain [15], whereas the seaweed-derived
Nocardiopsis sp. 03N67 collected in the Arctic Ocean afforded a new diketopiperazine,
cyclo-(L-Pro-L-Met), which showed promising anti-angiogenesis activity [16].
It is widely known that variations in cultivation parameters can induce the expression
of so-called ‘silent’ BGCs, for which the biosynthetic enzymes have been identified but
no natural product has been isolated from laboratory cultures [17]. Hence, changes in
abiotic factors such as nutrient availability (carbon, nitrogen, trace-elements), temperature,
salinity, and pH have been shown to influence the production of such ‘cryptic’ specialised
metabolites. Moreover, the chemical profile of a microorganism can depend on the culture
vessels, shaking conditions, and aeration, as well as on co-culturing techniques [18]. For
example, when glucose was substituted for glycerol in the ISP2 growth medium, the liquid
culture of Streptomyces sp. C34 isolated from the Atacama Desert, yielded ansamycin-
type polyketides [19]. Furthermore, the marine-derived Streptomyces sp. CHQ-64 was
found to produce new biologically active polyene-polyols and hybrid isoprenoid alkaloids
when cultured under shaking, whereas static fermentation yielded only one new metabo-
lite [20,21]. Therefore, the “One Strain Many Compounds” (OSMAC) approach [22] has
been a successful addition in the microbial drug discovery pipeline
Mass spectrometry approaches are often used to compare multi-strain metabolomics.
Molecular networking using the Global Natural Products Social Molecular Networking
(GNPS) infrastructure [23] has been deemed a valuable tool in the discovery of new
metabolites [24] as it provides rapid dereplication [25] and identification of unknown
parent ions. Clarinoside, a new pentalogin from the plant Mitracarpus scaber Zucc [26],
retimycin A, a non-ribosomal peptide from Salinispora arenicola [27], and deoxyphorbol
ester derivatives from Euphorbia dendroides [28] are a few of the specialised metabolites
discovered using MS-guided isolation based on the GNPS platform. Recently, further
analysis tools have been implemented on the GNPS infrastructure, such as MS2LDA
which provides fragmentation patterns of commonly co-occurring mass fragment peaks
and/or neutral losses that often represent molecular substructures (Mass2Motifs) [29], and
Network Annotation Propagation (NAP) [30] which improves in silico fragmentation of
the input data. The MolNetEnhancer workflow was introduced to combine the outputs
of the above-mentioned tools and add (putative) chemical class annotations to molecular
families in the molecular network [31].
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The sequencing of the first Streptomyces genome in 2002 [32] paved the way for the
discovery of further microbial natural products based on genomic data. The continuous
development of genome sequencing technology has led to a wealth of genomic data which
has motivated the development of sophisticated mining tools that can augment the search
and discovery of novel specialised metabolites [33,34]. Several of these [35] are publicly
accessible, enabling thorough and targeted genome mining of complex bacterial genomes,
including antiSMASH for the identification of secondary metabolites BGCs [36], ARTS for
high-throughput screening of bacterial genomes in reference to antibiotic production [37],
and BiG-SCAPE for clustering BGCs into Gene Cluster Families (GCFs) [38].
The linking of genome and metabolome mining outcomes to accelerate natural prod-
ucts discovery has shown great promise over the last decade, with several tools contributing
to bridging the gap between BGCs and mass spectra [39]. Although the term “metabologe-
nomics” was officially introduced in 2016 to describe correlations between BGCs and
metabolites [40], research on this approach started earlier. A study of actinomycete strains
in which their genomic data were linked with MS profiles, led to the identification of GCFs
for the previously reported natural products desertomycins and oasamycins, for which
the corresponding BGCs were unknown [41]. The authors were also able to isolate and
characterise a new chlorinated metabolite, tambromycin, and correlate it with its BGC in
11 actinomycete strains using metabologenomics [40]. Another successful study used a
combination of molecular networking and pattern-based genome mining approach from
which arenicolide A was linked to an uncharacterised BGC (PKS28) and the new metabolite,
retimycin A was identified, characterised and linked to the known NRPS40 pathway [27].
Herein, we introduce a novel unsupervised -omics integration method to link tandem
mass spectrometry data to BGCs to accelerate the analysis of large microbial natural
products datasets. NPlinker, a newly introduced software framework [42] was applied
for the first time to bridge the large metabolomics and genomics datasets of marine Polar
Actinobacteria. With the aid of the novel approach Rosetta, links between spectra and
BGCs for chloramphenicol and ectoine were established. Molecular networking of the
100 metabolite extracts derived from applying the OSMAC approach, showed growth
media specificity and potential chemical novelty was suggested. Moreover, the metabolite
extracts were screened for antibacterial activity and promising selective bioactivity against




Twenty-five strains, 14 Antarctic and 11 Arctic, were selected from a larger collec-
tion of Polar marine sediment bacteria mainly consisting of Actinobacteria [11], based
on taxonomy, isolation location (depths ranging from 388 to 4730 m) and previously
known metabolic profile of the strains. The selected strains belonged to seven rare acti-
nomycete genera—Pseudonocardia (eight strains), Micrococcus (seven strains), Rhodococcus
(three strains), Microbacterium (three strains), Kocuria (one strain), Agrococcus (one strain),
Dietzia (one strain). This genus-level delineation was well supported with bootstrap values
over 67% and all strains clade with their respective reference sequences. Additionally, one
strain of the phylum Proteobacteria, belonging to the Halomonas genus, was included in
the study (Figure 1, Table S1). In terms of core depth (Figure 1), the two Agrococcus, one
Kocuria and the eight Pseudonocardia strains were only isolated from the deepest sediment
cores at a depth greater than 4000 m, and the one Halomonas and the two Microbacterium
strains were only isolated from core depths of 1000–4000 m, while no pattern was observed
for the genera Micrococcus and Rhodococcus. Although these observations are interesting,
larger strain numbers would be required to draw statistical conclusions.
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Figure 1. Maximum likelihood tree based on 16S rRNA gene sequences of 25 strains isolated
from Antarctic (blue) and Arctic (green) sediment samples. Strain numbers are followed by a
symbol indicating the depth at which the sediment samples were collected from:  300–1000 m,
• 1000–4000 m, ♦ > 4000 m and # N/A (information missing). The accession number is shown in
brackets following the strain name.
2.2. Genome Mining
Genome assembly was carried out using SPAdes and due to the large numbers of
contigs obtained, MeDuSa was utilised for genome scaffolding, using reference strains
with >95% similarity based on 16S rRNA sequencing data (Table S2). No reference strains
with >95% sequence similarity could be identified for the Pseudonocardia strains; therefore,
they were eliminated from genome mining to avoid possible discrepancies.
Genome mining of the seventeen Polar rare Actinobacteria and the Proteobacteria
(Pseudonocardia strains excluded) revealed a total of 133 BGCs including NRPS, PKS, terpene
and RiPP classes. Interestingly, 37% of the total BGCs showed no homology to any BGC
within the MiBIG database and a further 30% suggested homology ranging from 2% to 63%
to known antibiotics. The biosynthetic diversity per strain is shown in the Circos diagram
(Figure 2). The width of the bands indicates the number of BGCs within each Natural
Product (NP) class which, as expected, is positively correlated to genome size. The lowest
number of BGCs was observed for small genomes such as the Micrococcus (2.4–2.7 Mbp) and
Agrococcus (3.1 Mbp) both of which had five BGCs, whereas the three Rhodococcus strains
(5.4–6.7 Mbp) revealed the largest number (17–22) of BGCs. Moreover, strains belonging
to the same genus showed BGCs of the same NP class (Table S3). The ectoine pathway
was observed in almost all genomes except the Kocuria (KRD140) and the Microbacterium
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(KRD174) strains. A similar pattern was observed for the terpene BGC which was present
in the genome of all Polar isolates except the Halomonas strain (KRD171) (Table S3). The
most abundant NP class was NRPSs which were not evenly distributed among all strains,
as the smaller genomes such as Micrococcus and Microbacterium did not show any NRPS
BGCs, although at least one NRPS-like fragment was identified in their genomes. On the
other hand, larger genomes such as the Rhodococcus strains revealed a high number of
NRPS BGCs (up to 10). Identification of siderophores based on bioinformatic analysis can
often be challenging as many siderophores are produced through NRPS pathways, thus
antiSMASH identifies them as NRPS and not siderophores [8,43]. Indeed, antiSMASH
identified two NRPS clusters in one Halomonas strain (KRD 171) and one Rhodococcus strain
(KRD 197) that have 53% and 63% gene homology to the serobactin and heterobactin
siderophore pathways, respectively. Only 10 BGCs belonging to the PKS family were
observed, of these, five were identified as Type I PKS, one Type II PKS, three Type III PKS,
and one heterocyst glycolipid synthase-like PKS (hgIE-KS).
Figure 2. BGC diversity by NP class and strain taxonomy across 17 Polar strains. The band colour depicts taxonomy
at the genus-level Micrococcus spp. (green), Kocuria sp. (purple), Rhodococcus spp. (orange), Halomonas sp. (dark blue),
Microbacterium spp. (light blue), Agrococcus sp. (teal) and Dietzia sp. (grey). Each coloured band can be traced from the
organism (right half of the circle) to the types of BGCs found in that genome (left half of the circle). The width of the band
represents the number of BGCs of that NP class. The outer rings on the left of the diagram show the number of the BGC
types found in each microbial genome. BGCs are colour coded based on the NP classification.
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The BGCs of the 17 Polar strains were further analysed using BiG-SCAPE, which
resulted in 80 GCFs, with 46% shown as singletons. As expected, there were BGCs present
in strains belonging to the same genus, that clustered in the same GCF. For example, the
ectoine BGCs present in the eight Micrococcus strains clustered in one GCF and the ectoine
BGCs of the three Rhodococcus strains were represented as an additional GCF (green circles
in Figure 3). The three Rhodococcus strains had a terpene BGC which showed low homology
(6%) to SF2575 BGC from the soil-derived Streptomyces sp. SF2575 [44] (blue circle in
Figure 3). Although the homology with the known biosynthetic pathway is low, the fact that
it is shared by all three BGCs from the different Rhodococcus strains, implies that the strains
may produce the same or similar metabolite(s) to the tetracycline antibiotic SF2575 [45].
Additionally, the three Rhodococcus strains (KRD12, KRD175, KRD197) showed an NRPS
BGC that shows low homology (11%) to the chloramphenicol BGC from Streptomyces
venezuelae ATCC 10712 [46]. Interestingly, only the gene clusters of KRD175 and KRD162
were grouped in the same family, whereas the corresponding BGC of KRD197 was shown
as a singleton (red circles in Figure 3) even running BiG-SCAPE with a high cut off (0.7).
Further investigation of the antiSMASH data showed that the predicted metabolites for
the NRPS genes of interest could be cyclic lipopeptides, which often exhibit antibiotic
properties [47].
Figure 3. BiG-SCAPE analysis of 17 strains. The 133 BGCs; 53 NRPS/NRPS-like, 20 Terpene, 10 PKS, 3 RiPP and 47
others (including BGCs such as ectoine, siderophore, betalactone) were clustered in 80 GCFs. Examples of GCFs of interest
are highlighted in coloured circles; red represents the Rhodococcus spp. NRPS BGC corresponding to a potentially new
cyclic lipopeptide, green represents the ectoine pathway found in all strains (here highlighted for the Micrococcus and
Microbacterium spp.) and blue the terpene BGC found in all three Rhodococcus strains with low homology to the known
antibiotic SF2575.
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2.3. Antibacterial Activity and Parent Ion Distribution
Culturing all strains in four growth media resulted in 100 metabolite extracts, of
which 72% exhibited activity against six pathogenic bacteria (Escherichia coli, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Enterococcus
faecalis) known as the “ESKAPE” pathogens [48]. Specifically, 39% of the biologically active
strains (28% of the total number) showed antibacterial activity against only one pathogen.
The same percentage of active extracts inhibited the growth of one or more pathogens
under only one cultivation condition. The inhibition zones ranged from 0.1 to 2.1 cm
(Table S4). Most of the bacterial metabolite extracts were active against S. aureus with the
Pseudonocardia strain KRD185 showing the largest inhibition zone (2.1 cm). Moreover, the 10-
fold diluted TSB extract of strain KRD185 showed promising antibacterial activity against
K. pneumoniae (0.9 cm) and A. baumannii (1.5 cm), whereas the A1M1 and 10-fold diluted
TSB extracts of Rhodococcus strain KRD175 were selectively active against K. pneumoniae
(Table S4). The occurrence of parent ions in relation to the bioactive extract is shown in
Figure 4 where Hinton diagrams are illustrating the number of parent ions produced only
by each strain (strain specific), as well as shared between two strains (Figure 4A). Strains
belonging to the same genus shared the highest number of produced parent ions, which
of course varies between the genera. For example, within the Micrococcus genus, strains
KRD022 and KRD026 share the highest number of parent ions (649 in total), whereas strains
KRD128 and KRD096 share only 287 parent ions. For the Pseudonocardia spp. isolates, there
is a wide variation in the number of shared parent ions (163–632), where strain KRD176
shares 632 ions with KRD196 and only 163 with KRD291. Variations ranging from 104
to 649 shared parent ions also occurred between strains of different genera, as expected.
The Microbacterium sp. strain KRD174 shared 104 and 123 parent ions with Micrococcus
sp. KRD096 and Pseudonocardia sp. KRD291, respectively, representing the lowest number
of shared ions. On the other hand, the Rhodococcus strain KRD175 showed the largest
number of shared parent ions (649) with strain KRD022 of the Micrococcus genus. The
sole Kocuria sp. isolate, KRD140, shared only 199 parent ions with Pseudonocardia strain
KRD176, but shared more than 400 ions with three Pseudonocardia strains (KRD182, KRD185,
KRD188). Amongst the Pseudonocardia strains, KRD182 showed the highest number of
shared parent ions with Micrococcus spp. (356–607 parent ions), and Rhodococcus strains
(465–612 parent ions). The Hinton diagram in Figure 4B demonstrates the number of parent
ions produced by strains under each growth condition (white box), as well as the number
of specific parent ions per strain grown under each growth condition (purple box) and the
observed bioactivity (black outline). The 10-fold diluted TSB metabolite extract of KRD185
(Pseudonocardia sp.) had the highest bioactivity, with a zone of inhibition of 2.1 cm, and
it produced the highest number of total (803) and unique (29) parent ions in that growth
condition when compared to the rest of the studied isolates. Although the Micrococcus
strain KRD022 produced the highest numbers of parent ions in ISP2 (819) and A1M1 (864)
media, it did not exhibit any biological activity against the pathogenic bacteria. These
two examples indicate that bioactivity is not necessarily related to the highest number of
produced metabolites (parent ions).
2.4. Molecular Networking
A molecular network of all 100 microbial metabolite extracts (25 strains cultured
in four media), in addition to the media and solvent blanks, consisted of 3107 parent
ions (nodes). There were 721 nodes that were excluded from the data analysis as they
corresponded to parent ions present in the media and solvent blanks. Of the total number
of parent ions produced (i.e., not present in the blanks, 2386), 414 of these nodes were
singletons indicating that their fragmentation pattern did not correlate with that of any
other parent ion, suggesting chemical novelty within the dataset. After ions in the media
controls were excluded, 23% (549) of ions were produced by strains grown in all four media.
A further 65% (1551) of ions were produced in more than one medium (i.e., not media
specific). Interestingly, the percentage of nodes which were media-specific was almost
Mar. Drugs 2021, 19, 103 8 of 21
constant across ISP2 (8.3%), ISP3 (8.8%), and 10-fold diluted TSB (8.0%) media, whereas
6.3% of the produced ions were present in the metabolite extracts derived from A1M1
medium. The MolNetEnhancer workflow showed 38 (putative) chemical classes annotated
in the molecular network (Figure 5B and Figure S2). Almost 71% of the produced ions did
not match any chemical classification which implies chemical novelty and is in accordance
with the low number of library hits generated by the GNPS molecular network. Fatty acyls,
and benzene and substituted derivatives represented 4% and 5% of the produced ions,
whereas prenol lipids covered 6% of the chemical classes identified in the network.
2.5. Computational Pattern Matching
A recently introduced software framework, NPLinker, was utilised to suggest links
between spectra of interest and their corresponding GCFs and therefore BGCs [42]. Initially,
analysis was carried out using the standardised strain correlation scoring method which
yielded potential MF-GCF links based upon correlating strain presence and absence. This
approach greatly narrowed the space of links requiring investigation. Further analysis of
the suggested links based on biosynthetic knowledge allowed the BGCs to be identified
that were likely to be most relevant to the metabolite of interest. Specifically, the GNPS
infrastructure allows parent ion clustering into molecular families and comparison of
observed spectra with GNPS embedded libraries. Simultaneously, BGCs were clustered
into GCFs via BiG-SCAPE. The generated MFs and GCFs were then uploaded to NPLinker
where potential MF-GCF links were ranked based on two scoring functions; standardised
strain correlation scoring and the here introduced, novel approach named Rosetta scoring
(Figure 6A).
Figure 4. (A) Hinton diagram showing the number of parent ions (proportional to the size of white box) produced by each
strain (max. 1041, min. 543 parent ions) and shared by each pair of strains (max. 670, min. 104 parent ions. Number of
parent ions specific to that strain (or pair) are proportional to the size of the inner purple box. (B) Hinton diagram showing
the number of parent ions by strain across each media (white box). Parent ions specific to only that strain-medium are also
shown (purple box). The thickness of black box outline corresponds to the number of ESKAPE pathogens bioactivity was
observed against (ranging from 1 to 6). For example, the bacterial metabolite extract for KRD185 in diluted TSB was found
to be bioactive against all six pathogens, but no bioactivity was observed when the same strain was cultured in any of the
other tested media.
Mar. Drugs 2021, 19, 103 9 of 21
Figure 5. (A) Molecular network of 3107 parent ions produced by 25 strains cultured in four media and those found in
media and solvent blanks. Nodes are colour coded based on media: ISP2, ISP3, A1M1 and 10-fold diluted TSB. Grey
nodes represent media components, whereas orange nodes represent parent ions that are found in more than one different
medium. (B) Nodes are colour coded based on 36 chemical class terms annotated using MolNetEnhancer workflow. Orange
nodes represent parent ions that had no matches with any chemical class.
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Figure 6. (A) Molecular families (MFs) are created through molecular networking using the GNPS infrastructure and
parent ions of interest are identified through dereplication using GNPS embedded libraries and the Rosetta tool. Genome
mining data (antiSMASH) of the Polar strains were clustered in GCFs using BiG-SCAPE. The GNPS (MFs) and BiG-SCAPE
(GCFs) outputs are then analysed with NPLinker to rank potential MF-GCF links using two scoring functions (standardised
strain correlation linking and Rosetta scoring). (B) The ectoine metabolite produced by two Rhodococcus spp. (KRD175 and
KRD197) when cultured in ISP3 and one Halomonas sp. (KRD171) cultured in A1M1 was linked with its corresponding
ectoine BGC via NPLinker.
2.5.1. Computational Pattern Matching Using the Standardised Strain Correlation
Scoring Method
The parent ion (m/z 547.3815) produced by Microbacterium sp. KRD174 cultured in
A1M1 showed spectral similarity to the GNPS spectrum CCMSLIB00000569369 suggest-
ing it was an antimycin-related metabolite. Through NPLinker, it was shown that this
metabolite could potentially be linked with the NRPS-like, betalactone, t3PKS and terpene
BGCs (KRD174). Although the standardised strain correlation score for all links was high
(2.7–4, with 4 being the maximum value observed in the dataset), when this information
was combined with the fact that antimycins are produced by an NRPS/PKS hybrid [49], it
was hypothesised that the betalactone and terpene BGCs were less likely to be involved
in the biosynthesis of the metabolite of interest. Of course, further validation studies are
required to confirm the responsible BGC. Similarly, another metabolite (m/z 521.3294)
showed similarity with GNPS spectrum CCMSLIB00004710288 for conglobatin (MIBiG
ID: BGC0001215), suggested that it could potentially be structurally related to the known
macrolide conglobatin originally isolated from the antibiotic-producing Streptomyces con-
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globatus [50]. The metabolite of interest was produced by two Micrococcus strains, KRR022
and KRD026 (diluted TSB medium), in addition to Rhodococcus sp. KRD175 (diluted TSB
medium) and two Pseudonocardia strains KRD184 and KRD291 (ISP2 medium). Using the
standardised strain correlation scoring method, the spectrum was potentially linked with
14 GCFs; two from Micrococcus sp. (KRD026) and 12 from Rhodococcus sp. (KRD175). How-
ever, the highest standardised strain correlation linking score (2.1) was observed for the
hybrid BGC arylpolyene-NRPS (KRD026) as well as for the NRPS, NRPS-like, arylpolyene
and butyrolactone BGCs (KRD175). Considering that conglobatin biosynthesis is governed
by an NRPS/PKS BGC [51], the arylpolyene-NRPS BGCs are most likely to be involved in
the biosynthesis, but further studies would be required to validate this. These examples
demonstrate that using spectral library matches with the standardised scoring method
included within NPLinker can narrow down possible MF-GCF links and thus enable a
more focused downstream analysis.
2.5.2. Computational Pattern Matching Using Standardised Strain Correlation Scoring and
the Rosetta Method
To further investigate the potential links between the genomics and metabolomics
datasets of the Polar strains, an additional filter layer was added into NPLinker which
allowed the use of the standardised strain correlation scoring method and the Rosetta
hit list simultaneously. This approach led to linking spectrum ID 219769 (m/z 185.1012),
putatively identified as ectoine ([M + CAN + H]+ adduct), via Rosetta, with the ectoine
BGC in two Rhodococcus sp. (KRD175, KRD197) and Halomonas sp. (KRD171) strains.
Interestingly, when using only the standardised scoring the same spectrum was linked to
40 GCFs. However, applying the additional Rosetta scoring method narrowed it down to
two GCFs (Figure 6B). Moreover, Rosetta identified that spectrum ID 111427 (m/z 380.2794)
could be structurally related to the known antibiotic chloramphenicol, originally isolated
from Streptomyces venezuelae [52]. The parent ion of interest was present in the metabolite
extracts of Rhodococcus sp. KRD175 and Micrococcus sp. KRD128 and was linked with
the NRPS BGC (KRD175) which showed homology to the chloramphenicol BGC. It is
important to note that the Rosetta scoring approach is limited by the number of MiBIG
BGCs for which experimental spectra are available. Due to the relatively low number of
publicly available spectra of microbial metabolites [53], the combined filtering approach
(standardised score and Rosetta) could only identify links for ectoine and chloramphenicol
to their corresponding BGCs. It must be pointed out that the Rosetta hits were a result of
matching single MS fragments to publicly available MS/MS datasets (Table S5), hence the
aforementioned metabolites could be only putatively identified. However, this workflow
clearly shows the promise of the implemented method for analysing large genomics and
metabolomics datasets.
3. Discussion
Over the years, it has been shown that the Arctic and Antarctic marine environment
host a vast variety of Actinobacteria with great potential for producing novel chemistry
with a wide range of biological activities [11–13]. Bioprospecting for new specialised
metabolites from Polar strains has greatly improved by the advancement of publicly
available tools for untargeted metabolomics [23] and genome mining [54], which are
continuously under development to meet the rapidly evolving field of microbial natural
products discovery. One of the main challenges of genome mining is the quality of the
genome assembly and annotation which can affect the outcome of the analysis [55,56].
A large number of contigs in the genome assembly can lead to BGCs, especially PKS-I
and NRPS, to be broken across pieces and not being identified by available software and
tools. A great example of such issue was demonstrated by Baltz who showed that draft
genomes containing large NRPS/PKS-I genes were incorrectly assembled due to being
largely fragmented which resulted in overestimation of such BGCs by antiSMASH 3.0 [57].
However, since then, new updated versions of antiSMASH have been released in which
the location of the gene cluster close to the contig edge is flagged. Moreover, the need
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for closed genomes is of paramount importance for accurate and reliable genome mining.
However, long-read technologies are often required to achieve this, which comes with
greater expense and their own drawbacks such as high error frequencies and reliability [58].
A recent study of nine Actinobacterial species, including three Pseudonocardia strains
used short-read (Illumina MiSeq) and long-read (Oxford Nanopore MinION) sequencing
technologies to analyse BGC fragmentation. The authors found that the MinION-based
genome assemblies increased the sensitivity related to BGC annotation and reduced the
number of fragmented BGCs. [56]. In this present study we omitted the Pseudonocardia
strains from the genomic analysis due to lack of reference strains for genome scaffolding.
Genome mining of the 17 non-Pseudonocardia strains revealed a wide diversity of BGCs
with most of them having low homology to known BGCs which suggests biosynthetic
and chemical novelty. Terpene BGCs were present in almost every genome, which was
not surprising as recent studies have revealed a wide distribution of terpene synthases in
bacteria which has led to the development of a new hidden Markov model for terpene
synthases identification in bacterial genomes [58,59]. As expected, the number and variety
of BGCs increased for larger genome sizes such as the Rhodococcus strains. However, it was
unexpected to notice that smaller genomes such as Micrococcus, Halomonas and Kocuria were
lacking PKS and NRPS BGCs as actinomycetes are known to produce metabolites encoded
by those pathways [60,61]. A similar observation was made by Schorn et al. when studying
rare marine actinomycetes [8]. Although small genomes might not look as promising
from a natural products discovery perspective, it does not necessarily mean that they are
not worth further investigation. The sponge-associated Micrococcus sp. was reported to
produce a new antibacterial xanthone named microluside A [62] and marine Halomonas
strains have yielded new antibacterial and cytotoxic metabolites named loihichelins A−F
and aminophenoxazinones, respectively [63,64].
To further explore and investigate the observed BGCs in our Polar strains, analysis
showed the ectoine BGC present in all genomes; this is known to be ubiquitous as the
metabolite aids survival under extreme osmotic stress [65]. Moreover, the terpene BGC with
high homology (66%) to a known carotenoid BGC was present in all Micrococcus strains
and clustered in the same GCF. Carotenoids are terpenoids produced by all photosynthetic
organisms and some non-phototrophic organisms, and have several applications as food
colorants, feed supplements, nutraceuticals, and pharmaceuticals [66]. Terpene BGCs with
homology (>37%) to the isorenieratene BGC were observed in the Rhodococcus strains and
were clustered in the same GCF. Actinobacteria, and particularly Streptomyces spp., often
bear isorenieratene BGCs in their genome that are usually silent, and there have been only
a few cases in which these BGCs have been activated [67,68]. Furthermore, the genomic
data of the three strains belonging to the genus Rhodococcus suggest the presence of NRPS
BGCs which could potentially encode for cyclic lipopeptides. Such metabolites are of great
importance in drug discovery with the example of daptomycin, originally isolated from
the soil-derived Streptomyces roseosporus [69], which has been approved by the FDA as an
antibacterial agent against Gram positive pathogens [70].
For over 30% of the BGCs within our dataset, the most similar known cluster encoded
for an antibiotic. Of this, almost half showed low homology (<10%) with known BGCs.
This is an exciting finding suggesting that the rare actinomycete strains derived from Polar
marine sediments can potentially be a fruitful source of novel chemistry. It is worth noting
that extracting metabolites from culture broth in organic solvents was proven to be a more
effective and reliable method to assess biological activity (disc diffusion assay) than an
agar plug assay [71]. Although genome mining of the Rhodococcus spp. showed promising
potential for producing metabolites, the bioassay data did not fully support this. As only
strain KRD175 exhibited moderate but selective activity against K. pneumoniae. This could
be because the BGCs encoding for antibiotics remained silent or the biologically active
compounds were produced in low amounts that were not sufficient to inhibit the growth
of the pathogens. Moreover, the bacterial metabolite extracts mostly inhibited the growth
of S. aureus, whereas only a few showed inhibitory effects against K. pneumoniae and A.
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baumannii, which are two of the most drug-persistent pathogenic bacteria [72,73]. To the
best of our knowledge, there are only a few published reports on the inhibitory effects of
microbial specialised metabolites on A. baumannii [74–76] but none on K. pneumoniae; and
therefore, the Polar strains with such activity show promise to combat these pathogens.
Linking genomic and metabolomics datasets of actinomycete strains for specialised
metabolite discovery has been introduced only recently [41]. However, there is increased
interest in the scientific community to further explore this niche research field by generating
automated methods for correlating these complex datasets and ranking promising MF-GCF
links for further investigation. Targeted linking and automated approaches for accelerating
drug discovery have been reviewed [39,53]. Recently, metabolomic and genomic data of
72 isolates belonging to the rare actinomycete genus Planomonospora were analysed using
publicly available tools to link specialised metabolites to their corresponding BGCs [77].
The authors were able to manually pair siomycin congeners to a RiPP BGC and a new
salinichelin-like metabolite to the known BGC encoding for erythrochelin. In the present
study, the newly developed software, NPLinker, was used to link our experimental datasets
and prioritise strains for further chemical and biosynthetic investigation. The filtering
approaches that were implemented (standardised strain correlation score and Rosetta)
established links for ectoine and chloramphenicol to their corresponding BGCs but were
not yet sufficient to link the potentially new identified metabolites (antimycins-like and
conglobatin-like compounds) to GCFs as publicly available spectra of microbial metabolites
are almost non-existent and remain mostly hidden in supplemental figures in literature.
Van Santen et al. [78], among others, discussed the need for data sharing within the
scientific community which will allow the field of natural products to catch up with data-
centric approaches used in other research fields and further flourish. It is worth pointing
out that limiting number of Rosetta hits obtained within this metabolomics dataset is
indicative of the potential novel chemistry of the Polar strains which is further supported
by the large number of nodes that could not be annotated to specific chemical classes.
However, our findings agree with a recent literature review which reported only 29 new
metabolites isolated from Antarctic and Arctic bacteria, of which 13 have been discovered
from marine actinomycetes [13]. A future direction for NPLinker could be the integration
of bioassay data along with metabolomics and genomics datasets, as previously suggested
by others [79], which will give the opportunity to users to explore possible MF-GCF links
based on bioactivity and target the BGCs and therefore the metabolite(s) responsible for
the biological effect.
4. Materials and Methods
4.1. Phylogenetic Analysis
Twenty-four rare actinomycete strains and a marine strain of the phylum Proteobacte-
ria (Table S1) were previously isolated and taxonomically identified (through 16S rRNA
gene sequencing) from the Antarctic and sub-Arctic sediment core collection from two
separate studies in conjunction with the Scottish Association for Marine Sciences [11,12].
These strains were selected based on taxonomy and isolation location. Using the 16S
rRNA gene sequences, a maximum likelihood (ML) phylogenetic tree was constructed
(Kimura 2-parameter model, 1000 bootstraps) using Mega 7 (v 7.0.26) (https://www.
megasoftware.net/ (accessed on 9 November 2020)) [80,81] with visualisation and anno-
tation using FigTree (v 1.4.3) (http://tree.bio.ed.ac.uk/software/figtree (accessed on 9
November 2020)). The GenBank accession numbers for the 16S rRNA gene sequences are
the following: MT135519 (KRD153), MT135569 (KRD128), MT135795 (KR077), MT135986
(KRD070), MT136106 (KRD026), MT136242 (KRD012), MT136243 (KRD022), MT136510
(KRD096). The remaining strains were deposited in GenBank as mentioned in [11].
4.2. Fermentation and Metabolite Extraction
All twenty-five strains were pre-cultured (5 mL, 28 ◦C, 160 rpm for 7 days) in ISP2
medium [82], ISP3 medium [82] A1M1 medium [27] and 10-fold diluted TSB medium
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(BD™) prepared in distilled water. Instant ocean (18 g/L) was added in each of them. Each
culture [ISP2/ISP3/A1M1/10-fold dil. TSB medium (50 mL) with activated HP-20 resin
(Sigma) (2.5 g)] was inoculated (5% v/v pre-culture) and fermented (14 days, 28 ◦C, 160
rpm). The culture was then centrifuged (4000 rpm, 20 min), the supernatant removed, and
the cell/resin pellet lyophilised until dry (Thermo Savant MicroModulyo, Thermo Fisher
Scientific, Waltham, MA, USA). The lyophilised cell/resin pellet was extracted twice with
ethyl acetate (Fisher Scientific, Loughborough, UK, reagent grade) (20 mL, 100 rpm, 25 ◦C).
The extracts were combined, dried (under N2), the weight recorded and stored (4 ◦C).
4.3. Bioactivity Disc Diffusion Assay
Cultures in TSB (BD™) were prepared for Escherichia coli, Staphylococcus aureus, Kleb-
siella pneumoniae, Acinetobacter baumanii, and Pseudomonas aeruginosa, whereas cultures
in LB [peptone 10 g/L, yeast extract 5g/L, sodium chloride 5 g/L] (5 mL, 30 ◦C, 1200
rpm, 12 h) were prepared for Enterococcus faecalis. Nutrient agar (NA, 5 mL, ThermoFisher
Scientific) was inoculated with 0.1 mg/mL of the pathogen and was poured onto NA Petri
plates (10 mL). The ethyl acetate metabolite extracts were re-dissolved in ethyl acetate at a
concentration of 5 mg/mL and 20 µL was added onto each sterile disc (5 mm). The plates
were incubated overnight at 30 ◦C and the zones of inhibition were recorded (cm).
4.4. Bioactivity Agar Plug Assay
The 25 Polar strains were cultured in ISP2, ISP3, 10-fold diluted TSA and A1M1
media in 6-well plates (38 mm diameter/3 mL of media) until a uniform lawn was formed
(25 ◦C, 7–14 days). Cultures in TSB (BD™) and LB [peptone 10 g/L, yeast extract 5g/L,
NaCl 5 g/L] (5 mL, 30 ◦C, 1200 rpm, 12 h) were prepared for Escherichia coli, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Enterococcus
faecalis, respectively. NA (5 mL, Thermo Fisher Scientific) was inoculated with 0.1 mg/mL
of the pathogen and poured onto NA (10 mL). Plugs (8 mm) from each bacterial lawn
(grown for 14 days) were placed on the seeded pathogen plates and incubated overnight at
30 ◦C and the zones of inhibition were measured (cm).
4.5. Mass Spectral Data Acquisition
LC–MS/MS was performed using a Thermo Scientific Accela LC system coupled to a
Thermo Finnigan LTQ Orbitrap mass spectrometer with an ESI source. Bacterial metabolite
extracts and control media extracts (no bacteria) were prepared at 1 mg/mL in ACN
and were injected onto an ACE 5 (Hichrom) C18 column (5 µm, 75 × 3.0 mm) using the
following gradient: 1–5 min (5% ACN in H2O), 5–25 min (5–100% ACN), 25–30 min (100%
ACN). Mass data were collected in positive ion mode using ESI and mass range 150–1500
m/z (15,000 resolution). Data-dependent MS2 scans were obtained using collision-induced
dissociation (CID) with an energy of 35 eV and activation time of 30,000 ms for the first,
second, and third most intense peaks.
4.6. Mass Spectral Data Processing
Mass spectral data were processed using MZmine v2.38 freeware (http://mzmine.
sourceforge.net/ (accessed on 9 November 2020)) for peak detection, deconvolution, deiso-
toping, filtering, alignment and gap filling to make multiple data files comparable. Through-
out the data processing, the m/z tolerance used was 0.01, peaks were detected above 3.00E3
and the minimum time span and tR tolerance was 0.1 min. Mass detection was performed
using a centroid mass detector with a noise level set at 2.00 × 103.
4.7. Molecular Networking
The MS/MS data were converted from raw to mzXML file format using Proteowizard
MSConvert [83] and the data were uploaded to the GNPS server [23]. A molecular network
was created with the feature-based molecular networking workflow on the GNPS website (
http://gnps.ucsd.edu (accessed on 9 November 2020)). The data were filtered by removing
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all MS/MS fragment ions within +/−17 Da of the precursor m/z. MS/MS spectra were
window filtered by choosing only the top 6 fragment ions in the +/−150 Da window
throughout the spectrum. The precursor ion mass tolerance was set to 0.2 Da and a
MS/MS fragment ion tolerance of 0.2 Da. A network was then created where edges
were filtered to have a cosine score above 0.6 and at least 1 matched peak. Further,
edges between two nodes were kept in the network if and only if each of the nodes
appeared in each other’s respective top 10 most similar nodes. Finally, the maximum
size of a molecular family was set to 100, and the lowest scoring edges were removed
from molecular families until the molecular family size was below this threshold. The
spectra in the network were then searched against GNPS’ spectral libraries. The library
spectra were filtered in the same manner as the input data. All matches kept between
network spectra and library spectra were required to have a score above 0.6 and at least 1
matched peak (https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=124de327f32f47429
1a5037f41ac991d (accessed on 9 November 2020)). For molecular network visualisation,
Cytoscape version 3.6.1 was utilised [84] where each node corresponds to a consensus
spectrum and each edge represents a modified cosine similarity score between nodes. The
data used for the molecular networking analysis were deposited in the MassIVE Public
GNPS database under access number MSV000086584.
4.8. MolNetEnhancer Workflow Description for Chemical Class Annotation of Molecular Networks
To enhance chemical structural information within the molecular network, informa-
tion from in silico structure annotations from GNPS Library Search and Network Annota-
tion Propagation (NAP) were incorporated into the network using the GNPS MolNetEn-
hancer workflow (https://ccms-ucsd.github.io/GNPSDocumentation/molnetenhancer/
(accessed on 9 November 2020)) on the GNPS website [31]. Chemical class annotations
were performed using the ClassyFire chemical ontology [85]. (https://gnps.ucsd.edu/
ProteoSAFe/status.jsp?task=adbadc0707e7449dbe4de1562ecd7bd3 (accessed on 9 Novem-
ber 2020)).
4.9. Genomic DNA Extraction
All 25 Polar strains were cultured in ISP2 medium (5 mL, 30 ◦C, 200 rpm for 3 days).
High quality genomic DNA was isolated using an in-house protocol based on chemical
cell lysis followed by phenol/chloroform extraction [86]. The Pseudonocardia sp. strains
underwent cell lysis by vigorous vortexing (10 min) of the bacterial cultures with zirconium
oxide beads (~0.5 g) (Sigma-Aldrich Ltd., Dorset, UK). The purity and concentration of
the obtained genomic DNA was determined using a Nanodrop 2000 spectrophotometer
(Thermo Fisher Scientific) followed by measurements on Qubit 2.0 Fluorometer (Invitrogen,
Thermo Fisher Scientific, Waltham, MA, USA).
4.10. Genome Sequencing and Alignment
Whole-genome sequencing was carried out by Microbes NG (https://microbesng.
com/ (accessed on 9 November 2020)) as follows: Genomic DNA libraries were prepared
using Nextera XT Library Prep Kit (Illumina, San Diego, CA, USA) following the manu-
facturer’s protocol with the following modifications: two nanograms of DNA instead of
one were used as input, and PCR elongation time was increased to 1 min from 30 s. DNA
quantification and library preparation were carried out on a Hamilton Microlab STAR auto-
mated liquid handling system. Pooled libraries were quantified using the Kapa Biosystems
Library Quantification Kit for Illumina on a Roche light cycler 96 qPCR machine. Libraries
were sequenced on the Illumina HiSeq using a 250 bp paired-end protocol. Reads were
adapter trimmed using Trimmomatic 0.30 with a sliding window quality cut off of Q15 [87].
The closest available reference genome was identified using Kraken [88] the reads were
mapped with BWA mem for assessing the quality of the data. De novo assembly of the
reads was carried out utilising SPAdes [89]. MeDuSa [90] was utilised for genome scaffold-
ing, using reference strains with >95% similarity based on 16S rRNA sequencing data. The
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Pseudonocardia isolates were not analysed by MeDuSa as no reference strains were identi-
fied. The whole genome sequences for the polar strains have been deposited to GenBank
with the following accession numbers: SAMN14679891-SAMN14679907 (Table S2).
4.11. Biosynthetic Gene Cluster Mining and Comparison
The identification of BGCs was carried out using antiSMASH 5 beta [91]. The variety
and number of BGCs each Polar strain was visualised using the Circos diagram [92]. The
detected BGCs were grouped into Gene Cluster Families (GCF) using BiG-SCAPE 1.0 beta
(Navarro-Munoz et al. 2019), with the underlying assumption that similar BGCs, i.e.,
BGCs that belong to the same GCF, produce similar metabolites. BiG-SCAPE was run
using Longest Common Subcluster alignment mode, and cluster analysis carried out at the
default cutoff of 0.3.
4.12. Computational Pattern Matching
Computational prioritisation of links between BGCs and candidate products made
use of two complementary approaches. Firstly, the standardised strain correlation score
described in [42] was used to compute a score between each spectrum and each GCF. The
original strain correlation score introduced in [41] is heavily influenced by the number
of strains present in each spectrum or GCF making the ranking of links between spectra
and a particular GCF problematic. The standardised score overcomes this limitation,
permitting a more balanced ranking of spectra for each GCF independent of their size.
Significance values for each link were computed as described in [42]. Secondly, a novel
approach named Rosetta (code available here: https://github.com/sdrogers/nplinker/
tree/master/prototype/rosetta_data_prep (accessed on 9 November 2020)) based upon a
set of collated matches between the GNPS [23] library spectra and the MiBIG database of
characterised BGCs allows for putative links between individual spectra and BGCs to be
highlighted. The set consists of 2960 links, 2069 unique spectra, 249 unique MIBiG IDs. To
establish this set of collated links, the structural annotations available for both databases
were used. A pair of objects from the two datasets were matched if the first blocks of
the InChIKeys of the molecules in the GNPS library spectra and MiBIG validated gene
cluster products matched. Matching was restricted to the first block to avoid distinguishing
between molecules based on chemical properties that would not show up in the MS/MS
spectra (e.g., stereochemistry). With this set of collated links, observed spectra and BGCs
were putatively matched as follows: spectral similarity between measured MS2 spectra
and the relevant subset of the GNPS spectra was computed using the modified cosine score
(equivalent to “Analog search” in the GNPS framework). Results from antiSMASH were
parsed to extract the known cluster blast results and Rosetta links between spectra and
BGCs were generated where the spectra showed similarity to the GNPS spectrum and
the MiBIG entry was found in the known cluster blast record for the BGC. All analysis
was performed with the NPLinker framework [42] in which potential can be reported
using either one of these two scoring methods, or both simultaneously, with user-defined
thresholds.
Supplementary Materials: The following are available online at https://www.mdpi.com/1660-3
397/19/2/103/s1, Figure S1: Molecular network of 3107 parent ions produced by 25 Polar actino-
mycete strains. Nodes are colour coded based on genus: Agrococcus, Dietzia, Halomonas, Kocuria,
Microbacterium, Micrococcus, Pseudonocardia and Rhodococcus. Grey nodes represent media compo-
nents, whereas orange nodes represent parent ions that are produced by more than one different
medium. Figure S2: Pie chart showing the distribution of parent ions (%) between the 36 chemical
class terms shown in the legend as annotated by MolNetEnhancer. The percentage of parent ions
with no chemical class match (70.5%) is not shown in the pie chart Each class has been colour coded
to match the molecular network generated through MolNetEnhancer workflow analysis (Figure 5B).
Table S1: Isolation and collection data of the 25 polar bacteria. Table S2: Genome quality of the Polar
strains (Pseudonocardia strains were not analysed by MeDuSa as no reference strains were available).
Table S3: Identified BGCs using antiSMASH 5 clusters after genome scaffolding using MeDuSa.
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Table S4: Bioactive bacterial extracts organised by genus, strain name (KRD) and growth medium
ISP3, A1M1, ISP2, and 10-fold dil. TSB. Antibiotic activity against the clinical pathogens E. faecalis, S.
aureus, K. pneumoniae, A. baumannii, P. aeruginosa and E. coli is shown as zones of inhibition (cm) and
colour coded by inhibition zone size. Table S5: Putatively identified metabolites using the Rosetta
approach.
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Table S1: Isolation and collection data of the 25 polar bacteria. 
Ref. No Closest type stain Polar region Location Year of collection Length (cm) Type Depth (m) Section (B, M, U) 
KRD012 Micrococcus sp. Antarctica Antarctic PS61-139 N/R N/R N/R N/R N/A 
KRD022 Micrococcus sp. Antarctica PS67-16A, Agullas Basin 2005 N/R Box 4730 N/A 
KRD026 Micrococcus sp. Antarctica PS67-16A, Agullas Basin 2005 N/R Box 4730 N/A 
KRD070 Micrococcus sp. Arctic M5M-75-62-B4, Voring Plateau 2002 N/R Gravity 1358 N/A 
KRD077 Micrococcus sp. Arctic M5M-75-62-B4, Voring Plateau 2002 N/R Gravity 1358 N/A 
KRD096 Micrococcus sp. Arctic M5M-127b-99b8, Kongsfjord Outer 2005 N/R Piston 388 N/A 
KRD128 Micrococcus sp. Arctic 
M5M-219-143A, Northern Svalbard 
Margin 
2007 N/R Piston N/R N/A 
KRD140 Kocuria sp. Antarctica Antarctic PS66-88A, Weddell Abyssal P. 205 N/R multi 4932 N/A 
KRD153 Micrococcus sp. Arctic M5M-219-142B N/R N/R N/R N/R N/R 
KRD162 Rhodococcus sp. Antarctica PS61 138-8 (BC052-A) 2002 38 Box 4539 B 
KRD168 Pseudonocardia sp. Antarctica PS61 138-8 (BC052-A) 2002 38 Box 4539 B 
KRD169 Pseudonocardia sp. Antarctica PS61 138-8 (BC052-A) 2002 38 Box 4539 B 
KRD171 Halomonas sp. Arctic JR75 (GC067) 2002 77 Gravity 1226 M 
KRD172 Microbacterium sp. Arctic JR75 (GC067) 2002 77 Gravity 1226 M 
KRD174 Microbacterium sp. Arctic JR75 (GC067) 2002 77 Gravity 1226 M 
KRD175 Rhodococcus sp. Arctic JR75 (GC067) 2002 77 Gravity 1226 B 
KRD176 Pseudonocardia sp. Antarctica PS61 134-5 (BC043) 2002 45.5 Box 4060 U 
KRD182 Pseudonocardia sp. Antarctica PS61 134-5 (BC043) 2002 45.5 Box 4060 U 
KRD184 Pseudonocardia sp. Antarctica PS61 134-5 (BC043) 2002 45.5 Box 4060 M 
KRD185 Pseudonocardia sp. Antarctica PS61 134-5 (BC043) 2002 45.5 Box 4060 M 
KRD186 Agrococcus sp. Antarctica PS61 134-5 (BC043) 2002 45.5 Box 4060 B 
KRD188 Pseudonocardia sp. Antarctica PS61 134-5 (BC043) 2002 45.5 Box 4060 B 
KRD291 Pseudonocardia sp. Antarctica PS61 134-5 (BC043) 2002 45.5 Box 4060 B 
KRD197 Rhodococcus sp. Antarctica PS61 140-2 (BC055W) 2002 16 Box 2946 U 
KRD202 Dietzia sp. Arctic JR219 PC141 2010 86.5 Piston  N/R N/R 











Most frequent family 
(%) 






Total length (bp) N50 
KRD 012 SAMN14679891 Micrococcaceae (86.32) Micrococcus luteus (86.13) 587934 73,14 54 2428345 152950 
KRD 022 SAMN14679892 Micrococcaceae (87.14) Micrococcus luteus (86.94) 991624 72,5 634 2708943 48082 
KRD 026 SAMN14679893 Micrococcaceae (84.08) Micrococcus luteus (83.67) 777451 72,72 93 2630609 126029 
KRD 070 SAMN14679894 Micrococcaceae (84.26) Micrococcus luteus (84.04) 860196 72,96 61 2506630 120226 
KRD 077 SAMN14679895 Micrococcaceae (86.50) Micrococcus luteus (85.18) 897931 72,79 117 2553835 77566 
KRD 096 SAMN14679896 Micrococcaceae (87.02) Micrococcus luteus (86.67) 335398 72,99 91 2499004 167875 
KRD 128 SAMN14679897 Micrococcaceae (85.88) Micrococcus luteus (85.37) 
112082
6 
73,19 69 2447759 166662 
KRD 140 SAMN14679898 Micrococcaceae (34.9) Kocuria rhizophila (32.10) 253418 68,91 36 2743959 503418 
KRD 153 SAMN14679899 Micrococcaceae (87.30) Micrococcus luteus (87.09) 
201536
7 
72,87 82 2546919 127028 
KRD 162 SAMN14679900 Nocardiaceae (10.26) 
Rhodococcus erythropolis 
(3.16) 
470260 64,22 110 5901029 339827 
KRD 171 SAMN14679901 Halomonadaceae (2.03) Halomonas elongata (1.20) 577377 54,66 57 5542288 425172 





439847 66,7 38 3362075 
319652
4 







66,53 452 4823384 106614 
KRD 175 SAMN14679904 Nocardiaceae (9.63) 
Rhodococcus erythropolis 
(2.55) 
603595 64,67 82 5449128 432516 





293168 70,97 29 3101783 
304870
3 
KRD 197 SAMN14679906 Nocardiaceae (7.72) 
Rhodococcus erythropolis 
(1.59) 
569376 64,12 296 6781538 736182 
KRD 202 SAMN14679907 Nocardiaceae (5.01) 
Rhodococcus pyridinivorans 
(0.87) 
772984 70,01 101 5564907 341290 
N50: the length for which the collection of all contigs of that length or longer covers at least half an assembly 
[Type here] 
 









































































































































KRD012 Micrococcus 5 0 1 0 0 0 0 1 1 1 0 0 1 0 0 0 0 ⎯ 
KRD022 Micrococcus 5 0 1 0 0 0 0 1 1 1 0 0 1 0 0 0 0 ⎯ 
KRD026 Micrococcus 6 0 1 0 0 0 0 1 1 1 0 0 1 0 0 0 1 Arylpolyene-NRPS 
KRD070 Micrococcus 5 0 1 0 0 0 0 1 1 1 0 0 1 0 0 0 0 ⎯ 
KRD077 Micrococcus 5 0 1 0 0 0 0 1 1 1 0 0 1 0 0 0 0 ⎯ 
KRD096 Micrococcus 5 0 1 0 0 0 0 1 1 1 0 0 1 0 0 0 0 ⎯ 
KRD128 Micrococcus 5 0 1 0 0 0 0 1 1 1 0 0 1 0 0 0 0 ⎯ 
KRD140 Kocuria 5 0 1 0 0 1 0 1 1 1 0 0 0 0 0 0 0 ⎯ 
KRD153 Micrococcus 5 0 1 0 0 0 0 1 1 1 0 0 1 0 0 0 0 ⎯ 
KRD162 Rhodococcus 21 8 6 1 0 0 0 2 0 0 1 0 1 0 1 0 1 Lantipeptide/Ladderane 
KRD171 Halomonas 4 1 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 ⎯ 
KRD172 Microbacterium 5 0 2 0 0 0 0 1 0 0 0 0 1 0 0 0 1 t3PKS/ betalactone 
KRD174 Microbacterium 5 0 2 0 0 1 0 1 1 0 0 0 0 0 0 0 0 ⎯ 
KRD175 Rhodococcus 17 6 4 1 0 0 0 2 0 0 1 1 1 0 0 1 0 ⎯ 










































KRD202 Dietzia 7 1 1 1 0 0 0 2 0 1 0 0 1 0 0 0 0 ⎯ 
[Type here] 
 
Table S4: Bioactive bacterial extracts organised by genus, strain name (KRD) and growth medium ISP3, A1M1, ISP2, and 10-fold dil. TSB. 
Antibiotic activity against the clinical pathogens E. faecalis, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa and E. coli is shown as zones of 











































































Figure S1: Molecular network of 3107 parent ions produced by 25 Polar actinomycete strains. Nodes are colour-coded based on genus: 
Agrococcus, Dietzia, Halomonas, Kocuria, Microbacterium, Micrococcus, Pseudonocardia and Rhodococcus. Grey nodes represent media components 






Figure S2: Pie chart showing the distribution of parent ions (%) between the 36 chemical class terms shown in the legend as annotated by 
MolNetEnhancer. The percentage of parent ions with no chemical class match (70.5%) is not shown in the pie chart. Each class has been colour 
coded to match the molecular network generated through MolNetEnhancer workflow analysis (Figure 5B) 
 
